Compositions for delivery of therapeutics and other materials

• US 8,277,776 B2
• Filed: 11/24/2009
• Issued: 10/02/2012
• Est. Priority Date: 02/27/2002
• Status: Active Grant

• Current Assignee: Pharmain Corporation
• Original Assignee: Pharmain Corporation
• Inventors: Bolotin, Elijah M., Castillo, Gerardo M.
• Primary Examiner(s): Jones, D L
• Application Number:
  US12/625,498
• Publication Number:
  US 20100158806A1
• Time in Patent Office: 1,043 Days
• Field of Search: 424/1.11, 424/1.49, 424/1.65, 424/1.69, 424/1.73, 424/9.1, 424/9.2, 534/7, 534 10- 16
• US Class Current: 424/1.65
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 47/6911 the form being a liposome
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.

Claims

1. A method of delivering an active agent to a target site comprising administering a composition to a subject, the composition comprising:

a first molecule comprising;

a first hydrophobic group comprising a first metal binding domain (FMBD);

a metal ion chelated to the FMBD; and

an active agent comprising a second MBD (SMBD) coordinately bonded to said metal ion; and

a second molecule comprising;

a second hydrophobic group; and

a first hydrophilic group covalently linked to the second hydrophobic group;

wherein after administration of the composition to said subject, the active agent is released in a sustained manner.

2. The method of claim 1, wherein the composition further comprises:

a targeting group covalently linked to the hydrophilic group.

3. The method of claim 1, wherein the composition further comprises a third molecule comprising:

a third hydrophobic group;

a second hydrophilic group comprising a first and second end, with the first end covalently linked to the third hydrophobic group; and

a targeting group covalently linked to the second end of the second hydrophilic group.

4. The method of claim 1, wherein the composition further comprises:

a third metal binding domain (TMBD) covalently linked to the second hydrophobic group.

5. The method of claim 4, wherein the composition further comprises a third molecule comprising:

a third hydrophobic group;

a second hydrophilic group, comprising a first and second end, with the first end covalently linked to the third hydrophobic group; and

a targeting group covalently linked the second hydrophilic group.

6. The method of claim 4 wherein the composition further comprises:

a targeting group covalently linked the first hydrophilic group.

7. The method of claim 6 wherein the composition further comprises a third molecule comprising:

a third hydrophobic group;

a second hydrophilic group covalently linked to the third hydrophobic group.

8. The method of one of claims 1-7, wherein the FMBD, the SMBD, or the TMBD is selected from a nitrogen containing poly carboxylic acid, or a polypeptide.

9. The method of one of claims 1-7, wherein the metal ion is a transition metal ion (d-block of the periodic table).

10. The method of one of claims 1-7, wherein the active agent is a therapeutic agent.

11. The method of one of claims 2, 3, 5, 6, or 7, wherein the targeting group is selected from a group consisting of an antibody, a cell surface receptor ligand, a cell surface receptor binding drug, a cell surface binding saccharide ligand, an extracellular matrix ligand, a cytosolic receptor ligand, a growth factor, cytokine, incretin, a hormone, and lectin.

12. The method of one of the claims 1-7, wherein the FMBD, the SMBD, or the TMBD are individually selected from N-(hydroxyl-ethyl)ethylenediaminetriacetic acid;

Nitrilotriacetic acid (NTA);

Ethylenebis(oxyethylenenitrilo) tetraacetic acid;

1,4,7,10 tetraazacyclodo-decane-N,N′

,N″

,N′

″

-tetraacetic acid;

1,4,7,10, tetraaza-cyclododecane-N,N′

,N″

-triacetic acid;

1,4,7-tris(carboxymethyl)-10-(2′

-hydroxypropyl)-1,4,7,10-tetraazocydodecane;

1,4,7-triazacyclonane-N,N′

,N″

triacetic acid;

1,4,8,11 tetraazacyclotetra-decane-N,N′

,N″

,N′

″

-tetraacetic acid;

diethylenetriamine-entaacetic acid (DTPA);

ethylenedicysteine;

bis(aminoethanethiol)carboxylic acid;

triethylenetetraamine-hexaacetic acid;

ethylenediamine-tetraacetic acid (EDTA);

1,2-diaminocyclohexane-N,N,N′

,N′

-tetraacetic acid;

or metal binding polypeptide.

13. The method of claim 8, wherein the FMBD, the SMBD, or the TMBD is a metal binding polypeptide of formula:

(AxHy)p where A is any amino acid, H is histidine, x is an integer from 0-6, y is an integer from 1-6, and p is an integer from 1-6.

14. The method of one of the claims 1-7, wherein the hydrophobic group has a molecular weight ranging from about 50 to about 1000 Daltons.

15. The method of one of the claims 1-7, wherein the first, the second, or the third hydrophobic group comprises one or more linear fatty acyl groups with formula [CH₃(CH₂)_xC0-] where x is an integer from 6-50.

16. The method of one of the claims 1-7, wherein the first, the second, or the third hydrophobic group is a branched or straight chain C₅-C₅₀ alkyl, a substituted branched or straight chain C₅-C₅₀ alkyl, a poly-glycine, a substituted poly-glycine, poly-alanine, poly-valine, poly-leucine, poly-isoleucine, poly-phenylalanine, poly-proline, poly-methionine, phenyl, napthyl, cholesterol, vitamin D, or vitamin E.

17. The method of claims 1-7, wherein the first, the second, or the third hydrophobic group has a general formula [P_vN_wC_xH_yO_z-] where v is an integer from 0-3, w is an integer from 0-3, x is an integer from 8-48, y is an integer from 15-95;

and z is an integer from 1-13.

18. The method of one of the claims 1-7, wherein the first or the second hydrophilic group comprises a polymer selected from poly(ethylene glycol);

alkoxy poly(ethylene glycol);

methoxy poly(ethylene glycol);

dicarboxylic acid esterified poly(ethylene glycol) monoester;

poly(ethylene glycol)-diacid;

copolymer of poly(ethylene glycol);

poly(ethylene glycol) monoamine;

methoxy poly(ethylene glycol) monoamine;

methoxy poly(ethylene glycol) hydrazide;

methoxy poly(ethylene glycol) imidazolide;

block copolymer of poly (ethylene glycol);

poly-lactide-glycolide co-polymer;

polysaccharide;

oligosaccharides;

polyamidoamine; and

polyethyleneimine.

19. The method of claim 1 wherein the route of administration is intravenous.

20. The method of claim 1 wherein the active agent is a peptide.

21. The method of claim 1 wherein the subject is in need of treatment of an inflammatory disease wherein the inflammatory disease is rheumatoid arthritis.

22. The method of claim 21 wherein the route of administration is parenteral.